MRI perfusion in determining pseudoprogression in patients with glioblastoma

Robert J. Young, Ajay Gupta, Akash D. Shah, Jerome J. Graber, Timothy A. Chan, Zhigang Zhang, Weiji Shi, Kathryn Beal, Antonio M. Omuro

Research output: Contribution to journalArticle

73 Scopus citations

Abstract

We examine the role of dynamic susceptibility contrast (DSC) magnetic resonance imaging (MRI) perfusion in differentiating pseudoprogression from progression in 20 consecutive patients with treated glioblastoma. MRI perfusion was performed, and relative cerebral blood volume (rCBV), relative peak height (rPH), and percent signal recovery (PSR) were measured. Pseudoprogression demonstrated lower median rCBV (P=009) and rPH (P<.001), and higher PSR (P=039) than progression. DSC MRI perfusion successfully identified pseudoprogression in patients who did not require a change in treatment despite radiographic worsening following chemoradiotherapy.

Original languageEnglish (US)
Pages (from-to)41-49
Number of pages9
JournalClinical Imaging
Volume37
Issue number1
DOIs
StatePublished - Jan 1 2013

Keywords

  • Glioblastoma
  • MRI perfusion
  • Progression
  • Pseudoprogression

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'MRI perfusion in determining pseudoprogression in patients with glioblastoma'. Together they form a unique fingerprint.

  • Cite this

    Young, R. J., Gupta, A., Shah, A. D., Graber, J. J., Chan, T. A., Zhang, Z., Shi, W., Beal, K., & Omuro, A. M. (2013). MRI perfusion in determining pseudoprogression in patients with glioblastoma. Clinical Imaging, 37(1), 41-49. https://doi.org/10.1016/j.clinimag.2012.02.016